GPNMB overexpression is associated with extensive bone metastasis and poor prognosis in renal cell carcinoma

Zhai,Jian-Po; Liu,Zhen-Hua; Wang,Hai-Dong; Huang,Guang-Lin; Man,Li-Bo

doi:10.3892/ol.2021.13154

GPNMB overexpression is associated with extensive bone metastasis and poor prognosis in renal cell carcinoma

Authors:
- Jian-Po Zhai
- Zhen-Hua Liu
- Hai-Dong Wang
- Guang-Lin Huang
- Li-Bo Man
View Affiliations

Affiliations: Department of Urology, Beijing Jishuitan Hospital, Beijing 102200, P.R. China
Published online on: December 1, 2021 https://doi.org/10.3892/ol.2021.13154
Article Number: 36

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycoprotein non‑metastatic protein B (GPNMB) promotes bone metastasis (BM) in various types of cancer. However, GPNMB expression and its function in patients with renal cell carcinoma (RCC) and BM is still unknown. Therefore, the clinical significance of GPNMB and its biological function in RCC with BM was investigated in the present study. A total of 31 patients with RCC and BM were retrospectively collected. The association between GPNMB protein expression level on the primary tumor and the clinicopathological characteristics of the patients was analyzed. Kaplan‑Meier analysis was used to investigate the association between GPNMB expression and the prognosis of the patients. The effects of GPNMB inhibition on cell proliferation, migration and invasion in RCC cells were investigated using short hairpin (sh)RNA. High GPNMB expression level was significantly associated with the number (P=0.001) and the extent of BM (P=0.001), Fuhrman grade (P=0.037), and ERK expression level (P=0.003) of the primary tumor. In addition, GPNMB overexpression was significantly associated with poor prognosis with respect to overall survival time (P=0.001). Furthermore, a specific shRNA sequence targeting the GPNMB gene was constructed and transduced into the ACHN cell line, using a lentivirus vector to obtain a stable cell line with low mRNA expression level of GPNMB. Low GPNMB expression level inhibited RCC cell proliferation, which was measured using a Cell Counting Kit‑8 assay. Cell migration and invasion ability was significantly decreased in GPNMB knockdown RCC cells compared with that in cells transduced with the negative control shRNA. In addition, the protein expression levels of phosphorylated ERK were lower in the GPNMB shRNA‑transduced ACHN cells compared with those in the control cells. Therefore, these results suggested that GPNMB plays an important role in tumor progression in RCC with BM. Furthermore, it might serve as a predictive marker for BM and as a poor prognostic factor in RCC with BM. GPNMB downregulation suppressed the proliferation, migration and invasion of the RCC cells, which may be mediated through the inhibition of the ERK signaling pathway.

View Figures

View References

1	Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P: Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019. View Article : Google Scholar : PubMed/NCBI
2	Capitanio U and Montorsi F: Renal cancer. Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
3	Zheng T, Zhu C, Bassig BA, Liu S, Buka S, Zhang X, Truong A, Oh J, Fulton J, Dai M, et al: The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages. Int J Epidemiol. 48:1886–1896. 2019. View Article : Google Scholar : PubMed/NCBI
4	Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A and Bray F: International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015. View Article : Google Scholar : PubMed/NCBI
5	Guida A, Escudier B and Albiges L: Treating patients with renal cell carcinoma and bone metastases. Expert Rev Anticancer Ther. 18:1135–1143. 2018. View Article : Google Scholar : PubMed/NCBI
6	Molina AMD: A multidisciplinary approach for the management of earlier stage renal cell carcinoma. Urol Oncol. 36:15–16. 2018. View Article : Google Scholar : PubMed/NCBI
7	Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, et al: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 375:2246–2254. 2016. View Article : Google Scholar : PubMed/NCBI
8	Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, et al: Distribution of metastatic sites in renal cell carcinoma: A population-based analysis. Ann Oncoly. 23:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bosse D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL, Choueiri TK and McKay RR: Response of primary renal cell carcinoma to systemic therapy. Eur Urol. 76:852–860. 2019. View Article : Google Scholar : PubMed/NCBI
10	Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC and Geynisman DM: Treatment facility volume and survival in patients with metastatic renal cell carcinoma: A registry-based analysis. Eur Urol. 74:387–393. 2018. View Article : Google Scholar : PubMed/NCBI
11	Zhuo H and Zhou L: Gpnmb/osteoactivin: An indicator and therapeutic target in tumor and nontumorous lesions. Pharmazie. 71:555–561. 2016.PubMed/NCBI
12	Rose AAN, Biondini M, Curiel R and Siegel PM: Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. Pharmacol Ther. 179:127–141. 2017. View Article : Google Scholar : PubMed/NCBI
13	Truong DD, Kratz A, Park JG, Barrientos ES, Saini H, Nguyen T, Pockaj B, Mouneimne G, LaBaer J and Nikkhah M: A Human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells. Cancer Res. 79:3139–3151. 2019. View Article : Google Scholar : PubMed/NCBI
14	Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, et al: TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease. Mol Cancer Res. 17:1613–1626. 2019. View Article : Google Scholar : PubMed/NCBI
15	Sondag GR, Mbimba TS, Moussa FM, Novak K, Yu B, Jaber FA, Abdelmagid SM, Geldenhuys WJ and Safadi FF: Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling. Exp Mol Med. 48:e2572016. View Article : Google Scholar : PubMed/NCBI
16	Ono Y, Chiba S, Yano H, Nakayama N, Saio M, Tsuruma K, Shimazawa M, Iwama T and Hara H: Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na(+)/K(+)-ATPase. Biochem Biophys Res Commun. 481:7–12. 2016. View Article : Google Scholar : PubMed/NCBI
17	Tian F, Liu C, Wu Q, Qu K, Wang R, Wei J, Meng F, Liu S and Chang H: Upregulation of glycoprotein nonmetastatic B by colony-stimulating factor-1 and epithelial cell adhesion molecule in hepatocellular carcinoma cells. Oncol Res. 20:341–350. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tomihari M, Chung JS, Akiyoshi H, Cruz PD Jr and Ariizumi K: DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res. 70:5778–5787. 2010. View Article : Google Scholar : PubMed/NCBI
19	Jin R, Jin YY, Tang YL, Yang HJ, Zhou XQ and Lei Z: GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway. Oncol Rep. 39:3034–3040. 2018.PubMed/NCBI
20	Fiorentini C, Bodei S, Bedussi F, Fragni M, Bonini SA, Simeone C, Zani D, Berruti A, Missale C, Memo M, et al: GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res. 323:100–111. 2014. View Article : Google Scholar : PubMed/NCBI
21	Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG and Singh RK: Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-β Signaling at the tumor-bone interface. Cancer Res. 70:3494–3504. 2010. View Article : Google Scholar : PubMed/NCBI
22	Jianpo Z, Ning L, Hai W, Haidong W and Libo M: Expression of GPNMB, ERK, MMP3 and MMP9 in primary lesion and bone metastasis of renal cell carcinoma and their correlation. Cancer Res Prev Treat. 47:367–371. 2020.
23	Mayo JC, Hevia D, Quiros-Gonzalez I, Rodriguez-Garcia A, Gonzalez-Menendez P, Cepas V, Gonzalez-Pola I and Sainz RM: IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. J Pineal Res. Oct 13–2016.(Epub ahead of print). doi: 10.1111/jpi.12373.
24	Qin C, Liu Z, Yuan Y, Zhang X, Li H, Zhang C, Xu T and Wang X: Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy. Mol Med Rep. 9:851–886. 2014. View Article : Google Scholar : PubMed/NCBI
25	Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M and Siegel PM: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res. 5:1001–1114. 2007. View Article : Google Scholar : PubMed/NCBI
26	Rose AA and Siegel PM: Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol. 6:55–74. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ramani V, Teshima T, Tamura K, Chung JS, Kobayashi M, Cruz PD Jr and Ariizumi K: Melanoma-derived soluble DC-HIL/GPNMB promotes metastasis by excluding T-Lymphocytes from the pre-metastatic niches. J Nvest Dermatol. 138:2443–2451. 2018. View Article : Google Scholar : PubMed/NCBI
28	Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, et al: Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res. 16:2147–2156. 2010. View Article : Google Scholar : PubMed/NCBI
29	Li YN, Zhang L, Li XL, Cui DJ, Zheng HD, Yang SY and Yang WL: Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer. APMIS. 122:140–146. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ma RQ, Tang ZJ, Ye X, Cheng HY, Sun KK, Chang XH and Cui H: Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer. Arch Gynecol Obstet. 297:1235–1244. 2018. View Article : Google Scholar : PubMed/NCBI
31	Arosarena OA, Barr EW, Thorpe R, Yankey H, Tarr JT and Safadi FF: Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases. J Cell Physiol. 233:409–421. 2018. View Article : Google Scholar : PubMed/NCBI
32	Bhattacharyya S, Feferman L, Sharma G and Tobacman JK: Increased GPNMB, phospho-ERK1/2, and MMP-9 in cystic fibrosis in association with reduced arylsulfatase B. Mol Genet Metab. 124:168–175. 2018. View Article : Google Scholar : PubMed/NCBI
33	Okita Y, Kimura M, Xie R, Chen C, Shen LT, Kojima Y, Suzuki H, Muratani M, Saitoh M, Semba K, et al: The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB. Sci Signal. 10:eaak93972017. View Article : Google Scholar : PubMed/NCBI
34	Chen C, Okita Y, Watanabe Y, Abe F, Fikry MA, Ichikawa Y, Suzuki H, Shibuya A and Kato M: Glycoprotein nmb is exposed on the surface of dormant breast cancer cells and induces stem cell-like properties. Cancer Res. 78:6424–6435. 2018. View Article : Google Scholar : PubMed/NCBI
35	Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, et al: Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer. 121:177–183. 2019. View Article : Google Scholar : PubMed/NCBI
36	Tray N, Adams S and Esteva FJ: Antibody-drug conjugates in triple negative breast cancer. Future Oncol. 14:2651–2661. 2018. View Article : Google Scholar : PubMed/NCBI
37	Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, et al: Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 32:3659–3666. 2014. View Article : Google Scholar : PubMed/NCBI
38	Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, et al: A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 125:1113–1123. 2019. View Article : Google Scholar : PubMed/NCBI
39	Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, et al: MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMB. Clin Cancer Res. 22:6088–6098. 2016. View Article : Google Scholar : PubMed/NCBI
40	Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, et al: EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol. 33:1609–1619. 2015. View Article : Google Scholar : PubMed/NCBI
41	Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, et al: Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 32:3619–3625. 2014. View Article : Google Scholar : PubMed/NCBI